401 related articles for article (PubMed ID: 25185962)
21. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry.
Daudén E; Carretero G; Rivera R; Ferrándiz C; Llamas-Velasco M; de la Cueva P; Belinchón I; Gómez-García FJ; Herrera-Acosta E; Ruiz-Genao DP; Ferrán-Farrés M; Alsina M; Baniandrés-Rodríguez O; Sánchez-Carazo JL; Sahuquillo-Torralba A; Fernández-Freire LR; Vilar-Alejo J; García-Donoso C; Carrascosa JM; Herrera-Ceballos E; López-Estebaranz JL; Botella-Estrada R; Segovia-Muñoz E; Descalzo MA; García-Doval I;
J Am Acad Dermatol; 2020 Jul; 83(1):139-150. PubMed ID: 32213306
[TBL] [Abstract][Full Text] [Related]
22. Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.
Borren NZ; Ananthakrishnan AN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1736-1743.e4. PubMed ID: 30616024
[TBL] [Abstract][Full Text] [Related]
23. Adverse events from systemic therapies for psoriasis are common in clinical practice.
Pearce DJ; Higgins KB; Stealey KH; Balkrishnan R; Crane MM; Camacho F; Fleischer AB; Feldman SR
J Dermatolog Treat; 2006; 17(5):288-93. PubMed ID: 17092859
[TBL] [Abstract][Full Text] [Related]
24. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
25. Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry.
Galiano Mejías S; Carretero G; Ferrandiz C; Vanaclocha F; Daudén E; Gómez-García FJ; Herrera-Ceballos E; Belinchón-Romero I; Sánchez-Carazo JL; López-Estebaranz JL; Alsina M; Ferrán M; Torrado R; Carrascosa JM; Rivera R; Llamas-Velasco M; Jiménez-Puya R; Mendiola MV; Ruiz-Genao D; Descalzo MA; de la Cueva Dobao P;
Actas Dermosifiliogr; 2017; 108(1):52-58. PubMed ID: 27658689
[TBL] [Abstract][Full Text] [Related]
26. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Papp K; Gottlieb AB; Naldi L; Pariser D; Ho V; Goyal K; Fakharzadeh S; Chevrier M; Calabro S; Langholff W; Krueger G
J Drugs Dermatol; 2015 Jul; 14(7):706-14. PubMed ID: 26151787
[TBL] [Abstract][Full Text] [Related]
27. Possible paradoxical occurrence of inflammatory arthritis in patients with psoriasis treated with biologics: findings in the Biobadaderm cohort.
Ruiz-Genao D; Perez-Zafrilla B; Lopez-Estebaranz JL; Belinchón-Romero I; Carrascosa JM; Ferrán M; Vanaclocha F; Herrera-Ceballos E; García-Doval I;
Br J Dermatol; 2017 Mar; 176(3):797-799. PubMed ID: 27120993
[No Abstract] [Full Text] [Related]
28. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives.
Burden AD; Warren RB; Kleyn CE; McElhone K; Smith CH; Reynolds NJ; Ormerod AD; Griffiths CE;
Br J Dermatol; 2012 Mar; 166(3):545-54. PubMed ID: 22356636
[TBL] [Abstract][Full Text] [Related]
29. Safety of treatment with biologics for psoriasis in daily practice: 5-year data.
van Lümig PP; Driessen RJ; Berends MA; Boezeman JB; van de Kerkhof PC; de Jong EM
J Eur Acad Dermatol Venereol; 2012 Mar; 26(3):283-91. PubMed ID: 21435026
[TBL] [Abstract][Full Text] [Related]
30. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
[TBL] [Abstract][Full Text] [Related]
31. Pregnancy Outcomes in Women With Moderate-to-Severe Psoriasis From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Kimball AB; Guenther L; Kalia S; de Jong EMGJ; Lafferty KP; Chen DY; Langholff W; Shear NH
JAMA Dermatol; 2021 Mar; 157(3):301-306. PubMed ID: 33533924
[TBL] [Abstract][Full Text] [Related]
32. Safety concerns with current treatments for psoriasis in the elderly.
Di Caprio R; Caiazzo G; Cacciapuoti S; Fabbrocini G; Scala E; Balato A
Expert Opin Drug Saf; 2020 Apr; 19(4):523-531. PubMed ID: 32056449
[No Abstract] [Full Text] [Related]
33. Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time.
Carrascosa JM; Rivera N; Garcia-Doval I; Carretero G; Vanaclocha F; Daudén E; Gómez-García FJ; De-la-Cueva-Dobao P; Herrera-Ceballos E; Belinchón I; Alsina M; Sánchez-Carazo JL; Ferrán M; Lopez-Estebaranz JL; Pérez-Zafrilla B; Llamas M; Rivera R; Ferrándiz C;
Actas Dermosifiliogr; 2015 Oct; 106(8):638-43. PubMed ID: 26141003
[TBL] [Abstract][Full Text] [Related]
34. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up.
Reich K; Papp KA; Griffiths CE; Szapary PO; Yeilding N; Wasfi Y; Ott E; Hsu MC; Lebwohl M; Gordon KB;
J Drugs Dermatol; 2012 Mar; 11(3):300-12. PubMed ID: 22395580
[TBL] [Abstract][Full Text] [Related]
35. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).
Menter A; Papp KA; Gooderham M; Pariser DM; Augustin M; Kerdel FA; Fakharzadeh S; Goyal K; Calabro S; Langholff W; Chavers S; Naessens D; Sermon J; Krueger GG
J Eur Acad Dermatol Venereol; 2016 Jul; 30(7):1148-58. PubMed ID: 27027388
[TBL] [Abstract][Full Text] [Related]
36. [Side effects of biologic therapies in psoriasis].
Altenburg A; Augustin M; Zouboulis CC
Hautarzt; 2018 Apr; 69(4):290-297. PubMed ID: 29568996
[TBL] [Abstract][Full Text] [Related]
37. Three-year registry data on biological treatment for psoriasis: the influence of patient characteristics on treatment outcome.
Driessen RJ; Boezeman JB; van de Kerkhof PC; de Jong EM
Br J Dermatol; 2009 Mar; 160(3):670-5. PubMed ID: 19210502
[TBL] [Abstract][Full Text] [Related]
38. Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience.
Nieto Benito LM; Carretero G; Rivera-Díaz R; Carrascosa JM; Daudén E; de la Cueva P; Sahuquillo-Torralba A; Herrera-Acosta E; Baniandrés-Rodríguez O; Lopez-Estebaranz JL; Belinchón I; Riera-Monroig J; Ferrán M; Gómez-García FJ; Mateu A; Rodríguez L; Vilar-Alejo J; García-Donoso C; Ballescá F; Velasco LM; Botella-Estrada R; Herrera-Ceballos E; Ruiz-Genao DP; Descalzo MA; García-Doval I;
Actas Dermosifiliogr; 2022 Apr; 113(4):401-406. PubMed ID: 35428502
[TBL] [Abstract][Full Text] [Related]
39. A comparison of psoriasis drug failure rates and reasons for discontinuation in biologics vs conventional systemic therapies.
Levin AA; Gottlieb AB; Au SC
J Drugs Dermatol; 2014 Jul; 13(7):848-53. PubMed ID: 25007369
[TBL] [Abstract][Full Text] [Related]
40. Treatment modalities and risk of adverse events associated with biologic therapy: A 10-year observational review of the Australasian Psoriasis Registry.
Doolan BJ; Koye D; Ling J; Cains GD; Baker C; Foley P; Dolianitis C
Australas J Dermatol; 2021 Feb; 62(1):e47-e54. PubMed ID: 32885846
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
